Indaptus Net Income from 2010 to 2025
| INDP Stock | USD 9.89 0.57 5.45% |
Net Loss | First Reported 2015-03-31 | Previous Quarter -4.1 M | Current Value -4.5 M | Quarterly Volatility 4.2 M |
Check Indaptus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Indaptus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 698, Other Operating Expenses of 14.7 M or Research Development of 9.6 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.9. Indaptus financial statements analysis is a perfect complement when working with Indaptus Therapeutics Valuation or Volatility modules.
Indaptus | Net Income | Build AI portfolio with Indaptus Stock |
Latest Indaptus Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Indaptus Therapeutics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Indaptus Therapeutics financial statement analysis. It represents the amount of money remaining after all of Indaptus Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Indaptus Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Indaptus Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (15.02 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Indaptus Net Income Regression Statistics
| Arithmetic Mean | (15,044,981) | |
| Geometric Mean | 11,035,639 | |
| Coefficient Of Variation | (90.00) | |
| Mean Deviation | 9,502,837 | |
| Median | (7,693,664) | |
| Standard Deviation | 13,540,514 | |
| Sample Variance | 183.3T | |
| Range | 44M | |
| R-Value | (0.29) | |
| Mean Square Error | 180.2T | |
| R-Squared | 0.08 | |
| Significance | 0.28 | |
| Slope | (818,565) | |
| Total Sum of Squares | 2750.2T |
Indaptus Net Income History
Other Fundumenentals of Indaptus Therapeutics
| Net Income Applicable To Common Shares | ||
| Net Income From Continuing Ops | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Indaptus Therapeutics Net Income component correlations
About Indaptus Therapeutics Financial Statements
Indaptus Therapeutics shareholders use historical fundamental indicators, such as Net Income, to determine how well the company is positioned to perform in the future. Although Indaptus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Indaptus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Indaptus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -15 M | -15.8 M | |
| Net Loss | -12.9 M | -12.2 M | |
| Net Loss | -15 M | -15.8 M | |
| Net Loss | (1.61) | (1.69) | |
| Net Income Per E B T | 1.10 | 1.09 |
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.